FDA OKs New Antibody Drug Conjugate for HER2+ Breast Cancer FDA OKs New Antibody Drug Conjugate for HER2+ Breast Cancer

Trastuzumab deruxtecan is for the treatment of unresectable or metastatic HER2-positive breast cancer that has received two or more prior anti-HER2-based regimens in the metastatic setting.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news